Ascendis Pharma A/S
Ascendis Pharma A/S (ASND): 9 pipeline candidates · 3 upcoming catalysts · ~11 mo cash runway · 18 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
10.7 months
D/E -9.00 · 0% dilution
Lead: Approved
9 candidates
3 upcoming, next in ~714d
7 buys · 1 sell (180d)
A transparent, data-derived signal for Ascendis Pharma A/Sacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14.6B
Cash
$616.0M
Quarterly Burn
$214.0M
Runway
10.7 mo
Revenue
$247.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| chemotherapy | Phase 1/Phase 2 |
| Chemotherapy drug | Phase 1/Phase 2 |
| lonapegsomatropin | Phase 3 |
| Navepegritide | Phase 2 |
| skytrofa | Approved |
| somatropin | Phase 3 |
| TransCon IL-2 β/γ | Phase 2 |
| TransCon TLR7/8 Agonist | Phase 2 |
| yorvipath | Approved |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$38.4M
| Holder | Shares | Value |
|---|---|---|
| driehaus capital management llc | 127,562 | $29.2M |
| tudor investment corp et al | 38,600 | $8.8M |
| price t rowe associates inc /md/ | 1,530,345 | $350K |
Frequently asked questions
How many drug candidates are in Ascendis Pharma A/S's pipeline?
Ascendis Pharma A/S (ASND) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ascendis Pharma A/S's lead drug candidate?
Ascendis Pharma A/S's most advanced tracked candidate is chemotherapy (Phase 1/Phase 2) for Advanced Solid Tumor.
What is Ascendis Pharma A/S's next catalyst?
Ascendis Pharma A/S's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Effi" — expected June 1, 2028.
What is Ascendis Pharma A/S's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ascendis Pharma A/S has approximately 10.7 months of cash runway.
What is Ascendis Pharma A/S's market capitalization?
Ascendis Pharma A/S's market capitalization is approximately $14.6B.
Get the full picture on Ascendis Pharma A/S
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.